MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 05-16-2026
Syneos Health Operating Income 2011-2026 | SYNH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Syneos Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 403 M | 389 M | 293 M | 238 M | 160 M | -28.9 M | 155 M | 152 M | 63.6 M | 31.5 M | -37.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 403 M | -37.5 M | 165 M |
Quarterly Operating Income Syneos Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.2 M | -39.5 M | - | 118 M | 117 M | 73.9 M | - | 113 M | 83.7 M | 61 M | - | 98.8 M | 35 M | 49 M | 83.4 M | 69.4 M | 58.1 M | 26.8 M | 79.5 M | 39.8 M | 30.7 M | 10.2 M | 15 M | -88.9 M | 10.2 M | 34.8 M | 43.8 M | 39.4 M | 39.7 M | 32.5 M | 39.7 M | 44.3 M | 35.9 M | 32.4 M | 18.5 M | 22.7 M | 7.87 M | 14.6 M | 11.3 M | 15 M | 4.79 M | 370 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 118 M | -88.9 M | 39.1 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 20.54 | 2.55 % | $ 595 M |  USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 17.38 | 5.91 % | $ 525 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 118.01 | 2.64 % | $ 14.8 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 114.79 | 0.93 % | $ 34.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 116.57 | 1.29 % | $ 9.62 B |  Irlanda |
 |
Illumina
ILMN
|
-833 M | $ 144.83 | 2.05 % | $ 23 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 142.53 | 1.56 % | $ 6.66 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 3.71 | 55.23 % | $ 4.94 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.57 | 1.99 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 94.47 | -1.69 % | $ 6.38 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 430.1 | 1.95 % | $ 12.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 8.25 | 3.77 % | $ 736 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 158.86 | 1.77 % | $ 7.87 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.11 | 2.36 % | $ 1.17 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 19.04 | -1.14 % | $ 426 M | USA |
 |
Natera
NTRA
|
-541 M | $ 203.69 | -0.6 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 3.91 | 2.62 % | $ 362 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 27.15 | 1.53 % | $ 25.7 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 58.84 | 9.64 % | $ 3.52 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.16 | 7.88 % | $ 257 M | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
9.41 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.44 | 3.83 % | $ 5.6 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 255.75 | -0.65 % | $ 21.3 B | USA |
 |
Waters Corporation
WAT
|
271 M | $ 340.99 | -0.1 % | $ 20.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 449.37 | -0.54 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.63 | 3.42 % | $ 226 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Exagen
XGN
|
-14.1 M | $ 4.27 | 11.49 % | $ 92.1 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 8.86 | 0.34 % | $ 1.92 B | USA |